Merck unveils two strategic collaborations to enhance AI-driven drug discovery
The primary aim of these collaborations is to advance Merck's research endeavours and generate a range of innovative…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Sep 23
The primary aim of these collaborations is to advance Merck's research endeavours and generate a range of innovative…
20 Sep 23
Under the agreement, PeptiDream will leverage its PDPS technology to discover, optimise, and develop macrocyclic peptide candidates for…
19 Sep 23
Under the terms of the new agreement, Samsung Biologics will provide drug substance manufacturing for an antibody cancer…
15 Sep 23
The agreement provides Sun Pharma with rights to commercialise Tyvalzi (Sovateltide) for the treatment of acute cerebral ischemic…
14 Sep 23
The Swiss drugmaker will obtain rights to develop and commercialise therapeutic antibodies resulting from the collaboration, while AbCellera…
14 Sep 23
The companies will work together to promote the Devyser laboratory services to support and advance research and development…
13 Sep 23
The exclusive licensing partnership agreement provides Astellas with a total of up to €5.5m, in upfront and milestone…
13 Sep 23
The collaboration aims to expedite the development of an immuno-oncology product designed to treat specific cancers
12 Sep 23
SB17, a proposed biosimilar to Stelara (Ustekinumab), is Samsung Bioepis’ fourth candidate in the immunology pipeline, after SB4…
12 Sep 23
The partnership aims to pioneer innovative and transformative therapies for cancer patients facing substantial unmet medical needs